Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Coherus Biosciences (CHRS)
NASDAQ:CHRS
Coherus Biosciences (CHRS) Stock Price & Analysis
1,293 Followers
CHRS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.25 - $5.47
Previous Close$1.64
Volume1.85M
Average Volume (3M)1.66M
Market Cap
$188.15M
Enterprise Value$330.60M
Total Cash (Recent Filing)$259.77M
Total Debt (Recent Filing)$402.22M
Price to Earnings (P/E)―
Beta1.82
Next Earnings
Aug 01, 2024EPS Estimate
-$0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.79
Shares Outstanding114,725,740
10 Day Avg. Volume1,219,427
30 Day Avg. Volume1,661,408
Standard Deviation0.17
R-Squared0.04
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)-0.72
Price to Sales (P/S)2.49
Price to Cash Flow (P/CF)-3.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.10
Enterprise Value/Gross Profit3.36
Enterprise Value/Ebitda-24.11
Forecast
1Y Price Target
$8.50Price Target Upside418.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Coherus Biosciences News
Bulls Say, Bears Say
Bulls Say
Market PerformanceUdenyca came in at $42.7M in net sales, up 18% sequentially and 63% y/y, making significant gains in market share to 25%, up 10pps from 4Q23.
Product ApprovalThe FDA approved Udenyca Onbody, Coherus' on-body injector (OBI) formulation of Udenyca, offering unique, patient-friendly features and expanding into a large market segment.
Strategic PartnershipCoherus has entered an agreement to combine Loqtorzi with a first-in-class endothelin B receptor inhibitor for solid tumors including ovarian cancer.
Bears Say
Cash Flow ConcernsManagement's lack of commitment to cash flow positivity in 2024 could weigh on the stock.
Regulatory And Clinical RisksRisks include regulatory and clinical, as some products are not approved.
Revenue DeclineReported revenue of $77.1M declined down 16% sequentially based on lower recorded revenues of Cimerli.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CHRS FAQ
What was Coherus Biosciences’s price range in the past 12 months?
Coherus Biosciences lowest stock price was $1.25 and its highest was $5.46 in the past 12 months.
What is Coherus Biosciences’s market cap?
Currently, no data Available
When is Coherus Biosciences’s upcoming earnings report date?
Coherus Biosciences’s upcoming earnings report date is Aug 01, 2024 which is in 10 days.
How were Coherus Biosciences’s earnings last quarter?
Coherus Biosciences released its earnings results on May 09, 2024. The company reported $0.83 earnings per share for the quarter, beating the consensus estimate of -$0.254 by $1.084.
Is Coherus Biosciences overvalued?
According to Wall Street analysts Coherus Biosciences’s price is currently Undervalued.
Does Coherus Biosciences pay dividends?
Coherus Biosciences does not currently pay dividends.
What is Coherus Biosciences’s EPS estimate?
Coherus Biosciences’s EPS estimate is -$0.25.
How many shares outstanding does Coherus Biosciences have?
Coherus Biosciences has 114,725,740 shares outstanding.
What happened to Coherus Biosciences’s price movement after its last earnings report?
Coherus Biosciences reported an EPS of $0.83 in its last earnings report, beating expectations of -$0.254. Following the earnings report the stock price went down -10.377%.
Which hedge fund is a major shareholder of Coherus Biosciences?
Among the largest hedge funds holding Coherus Biosciences’s share is Woodline Partners LP. It holds Coherus Biosciences’s shares valued at 1M.
---
Coherus Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.50 (418.29% Upside)
$8.50 (418.29% Upside)
Blogger Sentiment
Bullish
CHRS Sentiment 66%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 77.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.55%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
89.74%
Trailing 12-Months
Company Description
Coherus Biosciences
Coherus BioSciences, Inc. is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.
---
CHRS Earnings Call
Q1 2024
0:00 / 0:00
---
CHRS Stock 12 Month Forecast
Average Price Target
$8.50
▲(418.29% Upside)
Technical Analysis
Best Analysts Covering CHRS
1 Year
1 Year Success Rate
2/21 ratings generated profit
1 Year Average Return
-33.60%
reiterated a buy rating 2 months ago
Copying Balaji Prasad's trades and holding each position for 1 Year would result in 9.52% of your transactions generating a profit, with an average return of -33.60% per trade.
---